D2C7-IT

Phase 2Small molecule

DDarell Bigner

D2C7-IT is one of 123 small molecule programs targeting Malignant Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

122

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant GliomaRecruiting

GBMRecruiting

GliomaActive, not recruiting

Newly DiagnosedRecruiting

Malignant GliomaPhase 1

Recruiting

GBMPhase 1

Recruiting

GliomaPhase 1

Active, not recruiting

Newly DiagnosedPhase 2

Recruiting

Competition

Competitive Landscape

103 competitors in Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

23 2

Paraplatin

AAvyxa

Phase 3

13 3

Voranigo

SServier

Phase 3

5 4

Ojemda

Day One Biopharmaceuticals

Phase 3

3 5

Opdivo

Bristol-Myers Squibb

Phase 2

13 6

Camptosar

Pfizer

Phase 2

5 7

Verzenio

Eli Lilly

Phase 2

3 8

Dostarlimab

Incyte

Phase 2

2 9

Oncovin

Eli Lilly

Phase 2

1 10

Lexapro

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Malignant Glioma

NCT04547777

Q4 2027

Phase 1Active, not recruiting

Glioma

NCT04160494

Q4 2028

Phase 1/2Recruiting

Newly Diagnosed

NCT05734560

Q1 2030

Phase 1Recruiting

GBM

NCT06455605

Clinical

Trials by Indication[1]

Malignant Glioma2 trials

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting·DDarell Bigner·Phase 1·NCT04547777·90 enrolled

Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma

Completed·DDarell Bigner·Phase 1·NCT02303678·81 enrolled

GBM1 trial

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Recruiting·DDarell Bigner·Phase 1·NCT06455605·46 enrolled

Glioma1 trial

D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting·DDarell Bigner·Phase 1·NCT04160494·18 enrolled

Newly Diagnosed1 trial

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting·DDarell Bigner·Phase 1/2·NCT05734560·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for D2C7-IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D2C7-IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D2C7-IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Darell Bigner company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDarell Bigner

D2C7-IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Q1 2030

Trials by Indication[1]

Malignant Glioma2 trials

GBM1 trial

Glioma1 trial

Newly Diagnosed1 trial

References

Drug Info

Quick Facts

Related News